Leslie Carol Botha: Birth control, i.e., synthetic hormone use is the largest uncontrolled medical experiment in history and is proving to be just that – an experiment – at the expense of millions of women worldwide. How can anyone think that suppressing natural hormone production could be healthy? It is not scientifically proven ANYWHERE. In addition, most women in the U.S. have tried three or more methods of contraception, and 29% have tried five or more methods. A lot of times they are switched back and forth between estrogen and progestin birth control like a ping pong ball – wreaking more havoc on the endocrine system.
Women have been duped again. Germaine Greer said this best:
“A woman’s body is the battlefield where she fights for liberation.
It is through her body that oppression works, reifying her, sexualizing her, victimizing her, disabling her.”
No wonder they never developed synthetic hormone birth control for men.
It is time to reclaim out pelvic goldmines from the pharmaceutical industry. Our survival is at stake.
Estrogen Plus Progestin Use Linked With Increased Breast Cancer Incidence and Mortality
March 29, 2013
Estrogen plus progestin use is linked with increased breast cancer incidence. In addition, prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be higher for hormone therapy users as well, according to a study published March 29 in the Journal of the National Cancer Institute.
In the Women’s Health Initiative (WHI) randomized trial, estrogen plus progestin was associated with an increase in both breast cancer incidence and mortality. However, most observational studies have linked estrogen plus progestin with more positive outcomes.
In order to determine the differences between the WHI trial and other observational studies, Rowan T. Chlebowski, M.D., Ph.D., Los Angeles Biomedical Research Institute (LA BioMed) lead researcher and colleagues, looked at postmenopausal women with no prior hysterectomy with negative mammograms within two years who were either users or non-users of estrogen and progestin combined therapy.
The researchers found that breast cancer incidence was higher in estrogen plus progestin users than incidence in nonusers. Women who started hormone therapy closer to menopause had a higher breast cancer risk with a weakening influence as the time from menopause increased.
“Because survival after breast cancer diagnosis did not differ between estrogen plus progestin users and nonusers, the higher breast cancer incidence of those using estrogen plus progestin may lead to increased breast cancer mortality on a population basis,” the authors write.